USP9X Antibody [H15M1] | Primary Antibodies

Application: Reactivity: Mouse, Human

Usage Information

Dilution
WB1:1000-1:10000 IP1:20 IHC1:50-1:100 IF1:100-1:250 FCM1:10-1:100

Application
WB, IP, IHC, IF, FCM

Reactivity
Mouse, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
290 kDa 117 kDa, 290 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
USP9X Antibody [H15M1] detects endogenous levels of total USP9X protein.

Clone
H15M1

Synonym(s)
DFFRX, FAM, USP9, USP9X, Ubiquitin carboxyl-terminal hydrolase 9X, Deubiquitinating enzyme FAF-X, Fat facets in mammals, Ubiquitin thioesterase FAF-X, Ubiquitin-specific-processing protease FAF-X, Hfam

Background
USP9X is an X‑linked ubiquitin-specific cysteine protease of the USP family that reverses ubiquitin conjugation on a broad spectrum of substrates and thereby controls their stability, localization, and participation in signaling pathways governing cell adhesion, polarity, survival, and lineage specification. The protein contains a large N‑terminal substrate- and scaffold-interacting region followed by a conserved C19 peptidase catalytic domain that hydrolyzes Lys11-, Lys63-, Lys48-, and Lys6‑linked polyubiquitin chains on target proteins, allowing USP9X to selectively remove degradative or signaling-linked ubiquitin modifications and to act as a key regulator of protein turnover and complex assembly. Through deubiquitination of SMAD4, AMOT family proteins, β‑catenin complexes, and components of Notch and Wnt pathways, USP9X modulates TGF‑β/BMP, Hippo–YAP, Wnt/β‑catenin, and Notch signaling outputs, influencing transcriptional programs that control proliferation, differentiation, and stem and progenitor cell fate in multiple tissues. In neural development, high USP9X expression in embryonic and neural stem cells and its activity toward substrates involved in cytoskeletal dynamics and ankyrin-repeat proteins support axonal growth, neuronal migration, dendritic spine development, and synaptic connectivity, and partial loss-of-function mutations in USP9X cause a defined neurodevelopmental syndrome with intellectual disability, language impairment, and structural brain anomalies. Within polarized epithelia, USP9X associates with adherens and tight junction complexes and regulates cell–cell contact integrity by stabilizing junctional components, thereby linking deubiquitination to maintenance of epithelial architecture and barrier function and to the integration of polarity cues with downstream Wnt and Notch signaling. In cancer biology, USP9X exerts context-dependent effects by removing ubiquitin from factors such as MCL1, RICTOR, and other survival and growth pathway components, which enhances anti-apoptotic signaling and mTORC2–Akt pathway activity in some tumors, while in other contexts USP9X loss cooperates with oncogenic drivers by disrupting differentiation cues and polarity, illustrating dual tumor-promoting and tumor-suppressive roles that depend on tissue and stage. Deubiquitination of signaling mediators in Notch-driven malignancies, including breast cancer, positions USP9X as an integral component of oncogenic Notch signaling, and pharmacological inhibition of its catalytic activity reduces Notch pathway output and restricts tumor growth in preclinical models, highlighting its tractability as a drug target. USP9X also regulates ribosomal quality control by deubiquitinating factors at stalled ribosomes, contributes to peroxisomal import through PEX5 deubiquitination, and stabilizes epitranscriptomic regulators such as ALKBH3 and ALKBH5, integrating ubiquitin-dependent control of proteostasis with DNA repair and RNA modification pathways that influence genome and transcriptome integrity.

Background

USP9X is an X‑linked ubiquitin-specific cysteine protease of the USP family that reverses ubiquitin conjugation on a broad spectrum of substrates and thereby controls their stability, localization, and participation in signaling pathways governing cell adhesion, polarity, survival, and lineage specification. The protein contains a large N‑terminal substrate- and scaffold-interacting region followed by a conserved C19 peptidase catalytic domain that hydrolyzes Lys11-, Lys63-, Lys48-, and Lys6‑linked polyubiquitin chains on target proteins, allowing USP9X to selectively remove degradative or signaling-linked ubiquitin modifications and to act as a key regulator of protein turnover and complex assembly. Through deubiquitination of SMAD4, AMOT family proteins, β‑catenin complexes, and components of Notch and Wnt pathways, USP9X modulates TGF‑β/BMP, Hippo–YAP, Wnt/β‑catenin, and Notch signaling outputs, influencing transcriptional programs that control proliferation, differentiation, and stem and progenitor cell fate in multiple tissues. In neural development, high USP9X expression in embryonic and neural stem cells and its activity toward substrates involved in cytoskeletal dynamics and ankyrin-repeat proteins support axonal growth, neuronal migration, dendritic spine development, and synaptic connectivity, and partial loss-of-function mutations in USP9X cause a defined neurodevelopmental syndrome with intellectual disability, language impairment, and structural brain anomalies. Within polarized epithelia, USP9X associates with adherens and tight junction complexes and regulates cell–cell contact integrity by stabilizing junctional components, thereby linking deubiquitination to maintenance of epithelial architecture and barrier function and to the integration of polarity cues with downstream Wnt and Notch signaling. In cancer biology, USP9X exerts context-dependent effects by removing ubiquitin from factors such as MCL1, RICTOR, and other survival and growth pathway components, which enhances anti-apoptotic signaling and mTORC2–Akt pathway activity in some tumors, while in other contexts USP9X loss cooperates with oncogenic drivers by disrupting differentiation cues and polarity, illustrating dual tumor-promoting and tumor-suppressive roles that depend on tissue and stage. Deubiquitination of signaling mediators in Notch-driven malignancies, including breast cancer, positions USP9X as an integral component of oncogenic Notch signaling, and pharmacological inhibition of its catalytic activity reduces Notch pathway output and restricts tumor growth in preclinical models, highlighting its tractability as a drug target. USP9X also regulates ribosomal quality control by deubiquitinating factors at stalled ribosomes, contributes to peroxisomal import through PEX5 deubiquitination, and stabilizes epitranscriptomic regulators such as ALKBH3 and ALKBH5, integrating ubiquitin-dependent control of proteostasis with DNA repair and RNA modification pathways that influence genome and transcriptome integrity.

References
https://pubmed.ncbi.nlm.nih.gov/31443933/ https://pubmed.ncbi.nlm.nih.gov/28620049/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%